You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華康生物醫學(08622.HK)前三季度盈轉虧至660.2萬元
格隆匯 11-10 21:58

格隆匯 11 月 10日丨華康生物醫學(08622.HK)公佈,截至2020年9月30日止9個月,實現收入人民幣1409.9萬元,同比減少23.42%;毛利986.4萬元,同比減少25.17%;期內公司擁有人應占虧損660.2萬元,同期則盈利172.1萬元,每股虧損1.64分。

截至2020年9月30日止九個月,集團主要銷售產品男性體外診斷試劑產品的收益顯着減少。董事認為該顯着減少乃主要由於中國銷售大幅倒退。因為自從新型冠狀病毒(COVID-19)疫情爆發,中國多個省市已採取緊急公共衞生措施,並採取各種行動預防疫情傳播,包括採取人羣控制或居家政策或命令。疫情亦令公司的中國工廠停止生產及銷售約五個星期。由於疫情,公司的業務於2020年上半年受到嚴重影響。跟隨2020年7月後一系列管理改進及業務改造,公司的銷售於2020年第三季獲改善,2020年9月30日止三個月錄得約人民幣690萬元的銷售,較去年同期輕微增加約人民幣11.5萬元或約1.7%。收入減少主要來自中國的男性不育體外診斷試劑的銷售顯着地減少。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account